EWTXEdgewise Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$189M
- 21% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$72M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$43M | −$72M | −$114M | −$159M | −$191M | 21% |
| Net income | −$43M | −$68M | −$100K | −$134K | −$168K | 25% |
| Operating cash flow | −$34M | −$53M | −$92M | −$109M | −$144M | 32% |
| Capex | $668K | $6M | $6M | $1M | $256K | 80% |
| Stock-based comp | $4M | $11M | $18M | $25M | $35M | 41% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $8M | 286 | 139 |
| FY2024 | $8M | $36M | 307 | 104 |
| FY2023 | $4M | $10M | 128 | 105 |